Contribution of infection and vaccination to population-level seroprevalence through two COVID waves in Tamil Nadu, India.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
11
04
2023
accepted:
19
12
2023
medline:
25
1
2024
pubmed:
25
1
2024
entrez:
24
1
2024
Statut:
epublish
Résumé
This study employs repeated, large panels of serological surveys to document rapid and substantial waning of SARS-CoV-2 antibodies at the population level and to calculate the extent to which infection and vaccination separately contribute to seroprevalence estimates. Four rounds of serological surveys were conducted, spanning two COVID waves (October 2020 and April-May 2021), in Tamil Nadu (population 72 million) state in India. Each round included representative populations in each district of the state, totaling ≥ 20,000 persons per round. State-level seroprevalence was 31.5% in round 1 (October-November 2020), after India's first COVID wave. Seroprevalence fell to 22.9% in round 2 (April 2021), a roughly one-third decline in 6 months, consistent with dramatic waning of SARS-Cov-2 antibodies from natural infection. Seroprevalence rose to 67.1% by round 3 (June-July 2021), with infections from the Delta-variant induced second COVID wave accounting for 74% of the increase. Seroprevalence rose to 93.1% by round 4 (December 2021-January 2022), with vaccinations accounting for 63% of the increase. Antibodies also appear to wane after vaccination. Seroprevalence in urban areas was higher than in rural areas, but the gap shrunk over time (35.7 v. 25.7% in round 1, 89.8% v. 91.4% in round 4) as the epidemic spread even in low-density rural areas.
Identifiants
pubmed: 38267448
doi: 10.1038/s41598-023-50338-3
pii: 10.1038/s41598-023-50338-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2091Informations de copyright
© 2024. The Author(s).
Références
Wikipedia. List of states and union territories of India by population. https://en.wikipedia.org/wiki/List_of_states_and_union_territories_of_India_by_population (2020).
Johns Hopkins University & Medicine. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). (2021).
Mathieu, E. et al. Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus (2020).
Duarte, N. et al. Adapting serosurveys for the SARS-CoV-2 vaccine era. Open Forum Infect. Dis. 9, ofab632. https://doi.org/10.1093/ofid/ofab632 (2022).
doi: 10.1093/ofid/ofab632
pubmed: 35103246
Tré-Hardy, M., Cupaiolo, R., Wilmet, A., Beukinga, I. & Blairon, L. Waning antibodies in SARS-CoV-2 naive vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers. J. Infect. 83, 381–412. https://doi.org/10.1016/j.jinf.2021.06.017 (2021).
doi: 10.1016/j.jinf.2021.06.017
pubmed: 34161817
pmcid: 8214908
Abdullahi, A. et al. SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. Nat. Commun. 13, 6131. https://doi.org/10.1038/s41467-022-33792-x (2022).
doi: 10.1038/s41467-022-33792-x
pubmed: 36253377
pmcid: 9574797
Evans, J. P. et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci. Transl. Med. 14, 8057. https://doi.org/10.1126/scitranslmed.abn8057 (2022).
doi: 10.1126/scitranslmed.abn8057
Hatzakis, A. et al. Modelling SARS-CoV-2 binding antibody waning 8 months after BNT162b2 vaccination. Vaccines 10, 285 (2022).
doi: 10.3390/vaccines10020285
pubmed: 35214743
pmcid: 8876471
Perreault, J. et al. Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood 136, 2588–2591. https://doi.org/10.1182/blood.2020008367 (2020).
doi: 10.1182/blood.2020008367
pubmed: 33001206
Özbay Kurt, F. G. et al. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Front. Immunol. 13, 1012526 (2022).
doi: 10.3389/fimmu.2022.1012526
pubmed: 36311732
pmcid: 9597683
Bertrand, D. et al. Waning antibody response and cellular immunity 6 months after third dose SARS-Cov-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Am. J. Transplant. 22, 1498–1500. https://doi.org/10.1111/ajt.16954 (2022).
doi: 10.1111/ajt.16954
pubmed: 35007383
pmcid: 10149233
Peng, Q. et al. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. eBioMedicine https://doi.org/10.1016/j.ebiom.2022.103904 (2022).
doi: 10.1016/j.ebiom.2022.103904
pubmed: 36116215
pmcid: 9486036
Newman, J. et al. Neutralizing antibody activity against 21 SARS-CoV-2 variants in older adults vaccinated with BNT162b2. Nat. Microbiol. 7, 1180–1188. https://doi.org/10.1038/s41564-022-01163-3 (2022).
doi: 10.1038/s41564-022-01163-3
pubmed: 35836002
pmcid: 9352594
Wei, J. et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nat. Microbiol. 6, 1140–1149. https://doi.org/10.1038/s41564-021-00947-3 (2021).
doi: 10.1038/s41564-021-00947-3
pubmed: 34290390
pmcid: 8294260
Ward, H. et al. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Reg. Health - Europe 4, 100098. https://doi.org/10.1016/j.lanepe.2021.100098 (2021).
doi: 10.1016/j.lanepe.2021.100098
pubmed: 33969335
Aldridge, R. W. et al. SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort. Nat. Commun. 13, 4869. https://doi.org/10.1038/s41467-022-32265-5 (2022).
doi: 10.1038/s41467-022-32265-5
pubmed: 35982056
pmcid: 9387883
den Hartog, G. et al. Persistence of antibodies to severe acute respiratory syndrome coronavirus 2 in relation to symptoms in a nationwide prospective study. Clin. Infect. Dis. 73, 2155–2162. https://doi.org/10.1093/cid/ciab172 (2021).
doi: 10.1093/cid/ciab172
Choe, P. G. et al. Antibody responses 8 months after asymptomatic or mild SARS-CoV-2 infection. Emerg. Infect. Dis. 27, 928–931. https://doi.org/10.3201/eid2703.204543 (2021).
doi: 10.3201/eid2703.204543
pubmed: 33350923
pmcid: 7920668
Stone, M. et al. Evaluation of commercially available high-throughput SARS-CoV-2 serologic assays for serosurveillance and related applications. Emerg. Infect. Dis. 28, 672–683. https://doi.org/10.3201/eid2803.211885 (2022).
doi: 10.3201/eid2803.211885
pubmed: 35202525
pmcid: 8888213
Buss, L. F. et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 371, 288–292. https://doi.org/10.1126/science.abe9728 (2021).
doi: 10.1126/science.abe9728
pubmed: 33293339
Lau, E. H. Y. et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat. Commun. 12, 63. https://doi.org/10.1038/s41467-020-20247-4 (2021).
doi: 10.1038/s41467-020-20247-4
pubmed: 33397909
pmcid: 7782739
Lumley, S. F. et al. The duration, dynamics, and determinants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses in individual healthcare workers. Clin. Infect. Dis. 73, e699–e709. https://doi.org/10.1093/cid/ciab004 (2021).
doi: 10.1093/cid/ciab004
pubmed: 33400782
pmcid: 7929225
Forgacs, D. et al. The effect of waning on antibody levels and memory B cell recall following SARS-CoV-2 infection or vaccination. Vaccines 10, 696 (2022).
doi: 10.3390/vaccines10050696
pubmed: 35632452
pmcid: 9143792
Piñana, J. L. et al. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination. Bone Marrow Transplant. 58, 567–580. https://doi.org/10.1038/s41409-023-01946-0 (2023).
doi: 10.1038/s41409-023-01946-0
pubmed: 36854892
pmcid: 9974060
Siller, A. et al. Seroprevalence, waning and correlates of anti-SARS-CoV-2 IgG antibodies in Tyrol, Austria: Large-scale study of 35,193 blood donors conducted between June 2020 and September 2021. Viruses 14, 568 (2022).
doi: 10.3390/v14030568
pubmed: 35336975
pmcid: 8954543
Whitcombe, A. L. et al. Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. Clin. Transl. Immunol. 10, e1261. https://doi.org/10.1002/cti2.1261 (2021).
doi: 10.1002/cti2.1261
Krutikov, M. et al. Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): Prospective cohort study in England. Lancet Healthy Longev. 3, e13–e21. https://doi.org/10.1016/S2666-7568(21)00282-8 (2022).
doi: 10.1016/S2666-7568(21)00282-8
pubmed: 34935001
pmcid: 8676418
Bartsch, Y. C. et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat. Commun. 12, 1018. https://doi.org/10.1038/s41467-021-21336-8 (2021).
doi: 10.1038/s41467-021-21336-8
pubmed: 33589636
pmcid: 7884400
Lopman, B. A. et al. A framework for monitoring population immunity to SARS-CoV-2. Ann. Epidemiol. 63, 75–78. https://doi.org/10.1016/j.annepidem.2021.08.013 (2021).
doi: 10.1016/j.annepidem.2021.08.013
pubmed: 34425208
pmcid: 8379082
Stringhini, S. et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): A population-based study. Lancet 396, 313–319. https://doi.org/10.1016/S0140-6736(20)31304-0 (2020).
doi: 10.1016/S0140-6736(20)31304-0
pubmed: 32534626
pmcid: 7289564
DataKind Bengaluru & Development Data Lab. Covid19Bharat.org. https://covid19bharat.org/ (2022).
Malani, A. et al. Seroprevalence of SARS-CoV-2 in slums versus non-slums in Mumbai, India. The Lancet Global Health (2020). https://doi.org/10.1016/S2214-109X(20)30467-8
Mohanan, M., Malani, A., Krishnan, K. & Acharya, A. Prevalence of SARS-CoV-2 in Karnataka, India. JAMA 325, 1001–1003. https://doi.org/10.1001/jama.2021.0332 (2021).
doi: 10.1001/jama.2021.0332
pubmed: 33538774
pmcid: 7863009
Kish, L. A procedure for objective respondent selection within the household. J. Am. Stat. Assoc. 44, 380–387. https://doi.org/10.1080/01621459.1949.10483314 (1949).
doi: 10.1080/01621459.1949.10483314
Shenzhen YHLO Biotech Co. Ltd. Customer Notification: Sensitivity and Specificity of iFlash-SARS-Cov-2 IgG and IgM kits from Clinical Trials (2020).
Ortho Clinical Diagnostics. INSTRUCTIONS FOR USE—CoV2G (Version 4.2) (2020).
Rogan, W. J. & Gladen, B. Estimating prevalence from the results of a screening test. Am. J. Epidemiol. 107, 71–76 (1978).
doi: 10.1093/oxfordjournals.aje.a112510
pubmed: 623091
Levin, E. G. et al. Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84. https://doi.org/10.1056/NEJMoa2114583 (2021).
doi: 10.1056/NEJMoa2114583
pubmed: 34614326
Isaac, R. et al. The burden of COVID-19 infection in a rural Tamil Nadu community. BMC Infect. Dis. 21, 1110. https://doi.org/10.1186/s12879-021-06787-0 (2021).
doi: 10.1186/s12879-021-06787-0
pubmed: 34711193
pmcid: 8552615
Selvaraju, S. et al. Population-based serosurvey for severe acute respiratory syndrome coronavirus 2 transmission, Chennai, India. Emerg. Infect. Dis. 27, 586–589. https://doi.org/10.3201/eid2702.203938 (2021).
doi: 10.3201/eid2702.203938
pubmed: 33496222
pmcid: 7853587
Kumar, M. S. et al. Monitoring the trend of SARS-CoV-2 seroprevalence in Chennai, India, July and October 2020. Trans. R. Soc. Trop. Med. Hyg. 115, 1350–1352. https://doi.org/10.1093/trstmh/trab136 (2021).
doi: 10.1093/trstmh/trab136
Dayanand, D. et al. Community seroprevalence and risk factors for SARS-CoV-2 infection in different subpopulations in Vellore, India, and their implications for future prevention. Int. J. Infect. Dis. 116, 138–146. https://doi.org/10.1016/j.ijid.2021.12.356 (2022).
doi: 10.1016/j.ijid.2021.12.356
pubmed: 34971822
Laxminarayan, R. et al. SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: A prospective, active surveillance study. Lancet Infect. Dis. 21, 1665–1676. https://doi.org/10.1016/S1473-3099(21)00393-5 (2021).
doi: 10.1016/S1473-3099(21)00393-5
pubmed: 34399090
pmcid: 8363227
Murhekar, M. V. et al. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J. Med. Res. 152, 48–60. https://doi.org/10.4103/ijmr.IJMR_3290_20 (2020).
doi: 10.4103/ijmr.IJMR_3290_20
pubmed: 32952144
pmcid: 7853249
Murhekar, M. V. et al. SARS-CoV-2 antibody seroprevalence in India, August–September, 2020: Findings from the second nationwide household serosurvey. Lancet Glob. Health 9, e257–e266. https://doi.org/10.1016/S2214-109X(20)30544-1 (2021).
doi: 10.1016/S2214-109X(20)30544-1
pubmed: 33515512
pmcid: 7906675
Murhekar, M. V. et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020–January 2021. Int. J. Infect. Dis. 108, 145–155. https://doi.org/10.1016/j.ijid.2021.05.040 (2021).
doi: 10.1016/j.ijid.2021.05.040
pubmed: 34022338
pmcid: 8132496
Murhekar, M. V. et al. Seroprevalence of IgG antibodies against SARS-CoV-2 among the general population and healthcare workers in India, June–July 2021: A population-based cross-sectional study. PLoS Med. 18, e1003877. https://doi.org/10.1371/journal.pmed.1003877 (2021).
doi: 10.1371/journal.pmed.1003877
pubmed: 34890407
pmcid: 8726494
Jahan, N. et al. Seroprevalence of IgG antibodies against SARS-CoV-2 in India, March 2020 to August 2021: A systematic review and meta-analysis. Int. J. Infect. Dis. 116, 59–67. https://doi.org/10.1016/j.ijid.2021.12.353 (2022).
doi: 10.1016/j.ijid.2021.12.353
pubmed: 34968773
Covid19India. COVID19INDIA (Catalogue No. January 30, 2021, 2021).
World Health Organization. Vol. 49 (2021).
Thiruvengadam, R. et al. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: A test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect. Dis. 22, 473–482. https://doi.org/10.1016/S1473-3099(21)00680-0 (2022).
doi: 10.1016/S1473-3099(21)00680-0
pubmed: 34838183
Desai, D. et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: A test-negative, case-control study. Lancet Infect. Dis. 22, 349–356. https://doi.org/10.1016/S1473-3099(21)00674-5 (2022).
doi: 10.1016/S1473-3099(21)00674-5
pubmed: 34826383
Post, N. et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. PLoS ONE 15, e0244126. https://doi.org/10.1371/journal.pone.0244126 (2021).
doi: 10.1371/journal.pone.0244126
Moss, P. The T cell immune response against SARS-CoV-2. Nat. Immunol. 23, 186–193. https://doi.org/10.1038/s41590-021-01122-w (2022).
doi: 10.1038/s41590-021-01122-w
pubmed: 35105982
Meyer, B. Waning antibodies to SARS-CoV-2—Don’t panic. Lancet Reg. Health - Europe https://doi.org/10.1016/j.lanepe.2021.100115 (2021).
doi: 10.1016/j.lanepe.2021.100115
pubmed: 33972935
Grifoni, A. et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. Cell Host Microbe 30, 1788. https://doi.org/10.1016/j.chom.2022.10.017 (2022).
doi: 10.1016/j.chom.2022.10.017
pubmed: 36521443
pmcid: 9749374
Nguyen, T. H. O. et al. T cells targeting SARS-CoV-2: by infection, vaccination, and against future variants. Front. Med. (Lausanne) 8, 793102. https://doi.org/10.3389/fmed.2021.793102 (2021).
doi: 10.3389/fmed.2021.793102
pubmed: 35004764
Kedzierska, K. & Thomas, P. G. Count on us: T cells in SARS-CoV-2 infection and vaccination. Cell Rep. Med. 3, 100562. https://doi.org/10.1016/j.xcrm.2022.100562 (2022).
doi: 10.1016/j.xcrm.2022.100562
pubmed: 35474748
pmcid: 8872824
Almendro-Vázquez, P., Laguna-Goya, R. & Paz-Artal, E. Defending against SARS-CoV-2: The T cell perspective. Front. Immunol. 14, 1107803. https://doi.org/10.3389/fimmu.2023.1107803 (2023).
doi: 10.3389/fimmu.2023.1107803
pubmed: 36776863
pmcid: 9911802